Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers overcome suppression of immune response against bacterial pathogens

13.07.2017

A new therapeutic approach for pneumonia

Researchers from Charité – Universitätsmedizin Berlin were able to positively influence the immune response in severe viral and bacterial co-infection. Using a human lung tissue model, they were able to show that the immune mechanisms triggered by viral pathogens prevent the tissue from mounting an effective response against a simultaneously occurring bacterial infection.


Simulation of viral/bacterial pneumonia in a human lung tissue model.

Reproduced with permission of the European Respiratory Society ©: Eur Respir J 2017; 7: 1601953.

The researchers successfully tested a new drug-based treatment aimed at correcting this misguided immune response (which occurs, for instance, in cases of pneumonia). Results from this study have been published in the European Respiratory Journal*.

According to the World Health Organization (WHO), pneumonia counts among the five most frequent causes of death worldwide, with estimates suggesting that a child dies of pneumonia approximately every 15 seconds. Given that elderly people are also frequently affected, pneumonia remains one of the most significant health care issues of our time – with mortality rates unchanged for more than 70 years. There are several reasons behind this situation, the first being the development of increasing levels of bacterial resistance against antibiotic therapy.

Another is the fact that, so far, we have failed to find drugs which are effective against many of the pathogens responsible for pneumonia. “In most cases, the main problem is an immune or inflammatory response causing excessive organ damage,” explains Prof. Dr. Andreas Hocke of Charité's Department of Internal Medicine – Infectiology and Respiratory Diseases Unit.

In an effort to promote the development of new therapeutic approaches, the German Research Foundation (DFG) has been providing funding support to the SFB-TR84 Collaborative Research Center (which is dedicated to researching the fundamental mechanisms involved in pneumonia) since 2010.

As part of these DFG-funded efforts, Charité-based researchers, led by Prof. Dr. Andreas Hocke and Prof. Dr. Stefan Hippenstiel, have developed a human lung tissue model capable of simulating crucial characteristics of pneumonia. Most of the investigations of this type, which have been conducted across the globe, have been using cell cultures or animal models. Extrapolation limitations mean that some of the biomedical findings from these studies are difficult to translate to humans.

The new experimental approach allows researchers to create a three-dimensional tissue structure model, which makes it possible to simulate and study human pathogens and their disease mechanisms. “We were able to analyze the ways in which viruses and bacteria interact with human alveoli during the first hours following infection, and we were able to show that these differ from those seen in animal models,” says Dr. Johanna Berg, a researcher who is also the study's first author.

Working with Dr. Katja Zscheppang, she started by infecting human tissue with dangerous influenza viruses. The two researchers then proceeded to infect the tissue with pneumococci, in order to create a particularly severe form of pneumonia.

The immune system varies in its response to viruses and bacteria. The researchers worked on the premise that the immune system's response to the virus is directly responsible for inhibiting an equivalent response targeting bacterial pathogens. This places the bacteria at an advantage, and they are thus able to multiply inside, and cause damage to, the lung tissue. The experiment confirmed the researchers' assumptions. Following infection with the influenza virus, human lung tissue initially mounts a highly differentiated response.

“We were able to show that the immune response which is triggered by the virus has an adverse effect on a subsequent bacterial infection caused by pneumococci,” explains Dr. Berg. She adds: “The main factor involved in mediating the body's inflammatory response, interleukin-1 beta, is being inhibited in certain alveolar immune cells. This prevents any subsequent activation of the immune system, and may even suppress normal cellular repair mechanisms.”

In order to influence this faulty immune response, the researchers used a drug which is already undergoing clinical testing for use in other inflammatory diseases and cancer. “The substance inhibits tyrosine kinase-2, a protein responsible for mediating the lung's immune response to viral pathogens. By doing so, it restores the immune system's ability to fight the bacterial infection,” explains Prof. Hocke, the study's principal investigator.

Developed in conjunction with an industrial partner, this new therapeutic approach has been submitted for patent. The researchers are planning to conduct further studies involving human lung tissue models, which will look at potential feedback effects on the tissue's ability to fight viral pathogens. They are also hoping to develop a way to test their findings in a clinical trial.

*Johanna Berg, Katja Zscheppang, Diana Fatykhova, Mario Tönnies, Torsten T. Bauer, Paul Schneider, Jens Neudecker, Jens C. Rückert, Stephan Eggeling, Maria Schimek, Achim D. Gruber, Norbert Suttorp, Stefan Hippenstiel, Andreas C. Hocke. Tyk2 as a target for immune regulation in human viral/bacterial pneumonia. Eur Respir J 2017; 7: 1601953 [https://doi.org/10.1183/13993003.01953-2016]

Contact:
Prof. Dr. Andreas C. Hocke
Department of Internal Medicine – Infectiology and Respiratory Diseases
Charité – Universitätsmedizin Berlin
Tel: +49 30 450 553 477
Email: andreas.hocke@charite.de

Weitere Informationen:

http://www.charite.de
http://www.charite-inflab.de/hocke-lab/
https://www.sfb-tr84.de/

Manuela Zingl | idw - Informationsdienst Wissenschaft

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>